Department of Cardiology, Renmin Hospital of Wuhan University, Jiefang Road 238, Wuhan, 430060, People's Republic of China.
Hubei Key Laboratory of Metabolic and Chronic Diseases, Wuhan, 430060, People's Republic of China.
Cell Biol Toxicol. 2024 Mar 21;40(1):17. doi: 10.1007/s10565-024-09853-w.
Cardiovascular diseases (CVDs) are the main diseases that endanger human health, and their risk factors contribute to high morbidity and a high rate of hospitalization. Cell death is the most important pathophysiology in CVDs. As one of the cell death mechanisms, ferroptosis is a new form of regulated cell death (RCD) that broadly participates in CVDs (such as myocardial infarction, heart transplantation, atherosclerosis, heart failure, ischaemia/reperfusion (I/R) injury, atrial fibrillation, cardiomyopathy (radiation-induced cardiomyopathy, diabetes cardiomyopathy, sepsis-induced cardiac injury, doxorubicin-induced cardiac injury, iron overload cardiomyopathy, and hypertrophic cardiomyopathy), and pulmonary arterial hypertension), involving in iron regulation, metabolic mechanism and lipid peroxidation. This article reviews recent research on the mechanism and regulation of ferroptosis and its relationship with the occurrence and treatment of CVDs, aiming to provide new ideas and treatment targets for the clinical diagnosis and treatment of CVDs by clarifying the latest progress in CVDs research.
心血管疾病(CVDs)是危害人类健康的主要疾病,其危险因素导致高发病率和高住院率。细胞死亡是 CVDs 中最重要的病理生理学机制之一。作为细胞死亡机制之一,铁死亡是一种新的调控性细胞死亡(RCD)形式,广泛参与 CVDs(如心肌梗死、心脏移植、动脉粥样硬化、心力衰竭、缺血/再灌注(I/R)损伤、心房颤动、心肌病(放射性心肌病、糖尿病性心肌病、脓毒症性心脏损伤、阿霉素性心脏损伤、铁过载性心肌病和肥厚型心肌病)),涉及铁调节、代谢机制和脂质过氧化。本文综述了铁死亡的机制和调控及其与 CVDs 发生和治疗的关系的最新研究,旨在通过阐明 CVDs 研究的最新进展,为 CVDs 的临床诊断和治疗提供新的思路和治疗靶点。